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VH replacement (VHR) is a type of antibody gene rearrangement in which an upstream
heavy chain variable gene segment (VH) invades a pre-existing rearrangement (VDJ). In this
Hypothesis andTheory article, we begin by reviewing the mechanism of VHR, its develop-
mental timing and its potential biological consequences. Then we explore the hypothesis
that specific sequence motifs called footprints reflect VHR versus other processes. We
provide a compilation of footprint sequences from different regions of the antibody heavy
chain, and include data from the literature and from a high throughput sequencing experi-
ment to evaluate the significance of footprint sequences. We conclude by discussing the
difficulties of attributing footprints to VHR.
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CONTEXT, DEFINITION, AND POTENTIAL MECHANISMS OF
VH REPLACEMENT
Antibodies are heterotetrameric proteins comprised of two heavy
chains and two light chains that are formed through V(D)J recom-
bination to generate a highly diverse repertoire of antigen binding
receptors expressed by B cells. The recombinase activating gene
encoded proteins, RAG1 and RAG2, target conserved heptamer
and nonamers within recombination signal sequences (RSSs) to
cleave the DNA that flanks recombining gene segments that join
together to form the variable regions of antibody heavy and light
chains [reviewed in Ref. (1)]. Typical V(D)J recombination gener-
ates a signal joint and a coding joint, and the latter is further diver-
sified at the junction between the recombining gene segments by
mechanisms including P-addition, N-addition, and exonucleolytic
nibbling [reviewed in Ref. (2)]. Occasionally atypical rearrange-
ments occur, generating hybrid joints, open-and-shut joints, or
joints between RSSs that ordinarily do not recombine (2–5).
Antibodies can be further revised and diversified through
receptor editing of the light chain, somatic hypermutation, gene
conversion, and VH replacement (VHR). Receptor editing typi-
cally involves RAG-dependent leapfrogging rearrangements on the
same allele as the defective or autoreactive light chain, rearrange-
ment on other alleles (κ or λ) and/or RS deletion [which renders
preceding κ rearrangement non-functional, reviewed in Ref. (6)].
Abbreviations: CDR3, third complementarity determining region; cRSS, cryptic
recombination signal sequence; DH, antibody heavy chain diversity gene segment;
footprint 5-mer, pentameric nucleotide sequence attributed to VHR; GVHD, graft
versus host disease; IgH, antibody heavy chain; JH, antibody heavy chain joining gene
segment; RSS, recombination signal sequence; SLE, systemic lupus erythematosus;
VH, antibody heavy chain variable gene segment; VHR, VH replacement.
Somatic hypermutation is DNA point hypermutation carried out
by activation induced cytidine deaminase (AID) (7), and typically
signifies a T-cell dependent antibody response. Gene conversion,
in which homologous sequences from other V genes are grafted
into the functional V gene, is a common method of gene diver-
sification in chickens (8), rabbits and more recent examples have
been described in horses and humans (9), and appear to be AID-
dependent (10). The final category of antibody gene diversification
is VHR, which is the focus of this article. Replacement involves the
transfer (or invasion) of some or most of another V gene into an
existing gene rearrangement.
Darlow and Stott have reviewed the literature on VHR and
envision two broad mechanistic classes of V replacement (11).
The first, also termed “classical” VHR, consists of invasion of an
existing VDJ rearrangement by an upstream VH. In classical VHR
there is RAG-mediated cleavage at a cryptic RSS (cRSS) located
in the 3′ end of the previously rearranged VH gene. The cRSS
has a DNA sequence that differs from the conventional heptamer
that flanks the DH gene segment by one nucleotide, bolded in
the sequence that follows: 5′-TACTGTG-3′ (12) and is found in
~70% of murine VHs and over 90% of human VHs (13). Occa-
sionally other heptamers containing the 3′ GTG nucleotides can
be used, suggesting that the last three nucleotides of the cRSS
motif are critical (14, 15). The TGT within the cRSS is the codon
encoding the conserved cysteine at the junction between FR3 and
CDR3. The second class of replacement, according to Darlow
and Stott, involves the transfer of other sequences of homol-
ogy between different V genes at different sites, many of which
appear to also resemble cRSSs. Examples of this second cate-
gory of VHR have been described in antibodies cloned from
single B cells in human tonsils (16), in antibodies cloned from
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synovial tissue of patients with rheumatoid arthritis (17), and in
antibodies cloned from human mucosa associated lymphoid tissue
lymphomas (18). Alternatively or in addition to RAG-mediated
rearrangement, replacements in this second category may arise
due to AID-mediated homologous recombination events that
are unrelated to the putative cRSSs (11). However, the mech-
anism of type 2 replacement is far from resolved as recently
a non-AID-dependent form of replacement has been described
at the κ locus using human pre-B cell lines (19). As the mol-
ecular mechanism of type 2 replacement remains to be fully
elucidated, we will focus the remainder of our analysis in this
manuscript on classical VHR (which we refer to hereafter as “VH
replacement”).
During VHR, an upstream VH gene invades into the cRSS,
replacing all but the last few nucleotides of the previously
rearranged VH gene (Figure 1A). The remaining 3′ nucleotides
of the VH, DH, and JH gene segments are retained in the
new rearrangement. The extra nucleotides from the 3′ end of
the previous VH gene are sometimes referred to as a “foot-
print.” Nearly all human VH genes have between five and nine
nucleotides in the potential footprint, between the cRSS and
the RSS. Most primary RSS rearrangements delete several of
these nucleotides from the 3′ end, so the potential footprint
may not be easily recognizable. Moreover, during VHR, addi-
tional nucleotides can be deleted, so the footprint from the pri-
mary VH can be entirely lost during VHR. It is also possible
for more than one replacement rearrangement to occur on the
same heavy chain allele, a process referred to as “serial” or “suc-
cessive” VHR (Figure 1B) (20). An example of a heavy chain
rearrangement with more than one footprint sequence is given
in Figure 1C.
DEMONSTRATION OF VH REPLACEMENT IN CELL LINES AND
MOUSE MODELS
VH replacement was initially discovered in two different trans-
formed B cell lines (12, 22). In both of these early studies, B cells
with non-functional heavy chain gene rearrangements (VDJ−)
were able to generate functional heavy chains (VDJ+) by undergo-
ing further heavy chain rearrangement into the cRSS. Continued
VHR could also convert a functional VDJ+ rearrangement into
a non-functional one through the incorporation of an upstream
pseudo-VH gene (12).
The development of antibody heavy chain (IgH) knock-in mice
provided a formal demonstration of VHR in B cells in vivo. VHR
was documented in hybridomas derived from the 3H9 heavy chain
knock-in mouse (13). VHR and invasion of upstream DH gene
also occurred in a knock-in for the T15 heavy chain (15). Fur-
thermore, B cells from quasi-monoclonal mice, which have an
anti-(4-hydroxy-3-nitrophenyl) acetyl (NP) heavy chain knock-
in and can only produce λ light chains, due to homozygous
engineered κ deficiency, can lose reactivity to NP by VHR. Strik-
ingly, most secreted antibodies in the quasi-monoclonal mouse
appear to arise through VHR (23). VHR was also observed in mice
that were genetically engineered to contain two non-productively
rearranged heavy chain alleles. In these VDJ−/VDJ− mice, IgHs
were generated via VHR in a RAG-dependent manner (cross-
ing the VDJ−/VDJ− mice onto a RAG2 deficient background
V
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FIGURE 1 | (A) VH replacement: an upstream VH gene invades by
rearranging into a pre-existing rearrangement. RAG cleaves the
conventional recombination signal sequence (black triangle) of the invading
VH (light blue VH gene) and cleaves at a cryptic heptamer sequence (cRSS,
dashed white triangle) of the invaded VH gene (yellow VH gene). The
resulting rearrangement is shown on the second line of the diagram and
includes the DH and JH genes of the previous rearrangement and the new
VH gene. Also included in the VH replacement product is a remnant or
“footprint” of the preceding VH gene (denoted by a yellow box). Often the
products of VH replacement exhibit CDR3 elongation, due to the retention
of the footprint sequence (the CDR3 is indicated by the bar under the
sequence and the added length of the new CDR3 sequence including the
footprint (in red) is indicated by the black bar below the sequence.)
(B) Serial VH replacement. The same conventions are used as in (A) and a
longer CDR3 is generated, via the accumulation of footprint sequences. In
both panels, boxes denote exons, lines introns, triangles RSS and the
rearrangement is indicated by dashed black lines. This diagram is not drawn
to scale. (C) Long CDR3 sequence with possible VH replacement(s). Shown
is the nucleotide sequence of an expanded B cell clone that was recovered
from peripheral blood DNA of a patient with systemic lupus erythematosus
(SLE) that reveals a 91 nucleotide CDR3. Kowal et al. described an
anti-dsDNA H chain sequence comprised of a VH3-N-DH2-2-JH6, which has
similar features to this junction, although it was shorter (21). Sequences in
black font match the corresponding germline gene segments. Red font
denotes possible N-additions and yellow shading highlights potential
footprint sequences. Dashes indicate regions where sequences do not
overlap. FR3, framework region 3; CDR3, third complementarity
determining sequence; FR4, framework region 4.
resulted in a failure to generate IgM+ B cells) (24). The ability
of RAG1 and RAG2 to bind to the cRSS was also demonstrated
by electrophoretic mobility shift assays using VH4-34 cRSS versus
consensus 12-RSS sequences (25).
In all of the preceding mouse models, VHR conferred greater
diversity or functionality upon the B cell repertoire (i.e., there was
a selective pressure that favored VHR). In contrast, when VHR
was compared with conventional rearrangement, using a mouse
model with an out of frame VDJ rearrangement (VDJ−) that was
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knocked into the heavy chain locus, conventional rearrangement
on the other heavy chain allele occurred far more frequently (26).
Similarly, in the 56R anti-dsDNA heavy chain knock-in mouse,
receptor editing was far more efficient in B cells that were het-
erozygous rather than homozygous for 56R (27). One caveat to
the 56R study was that cells that had undergone VHR on one allele
but were still left with a functional copy of the DNA-reactive 56R
heavy chain on the other allele could be counter-selected.
VH REPLACEMENT IN BONE MARROW B CELLS
To gain further insight into the mechanism of VHR, studies were
performed in mice to determine its developmental timing. Several
studies suggest that VHR occurs at or near the time of conven-
tional IgH gene rearrangement. The junctions of IgH sequences
with evidence of VHR in IgH knock-in mice usually contain N-
additions (13). Terminal deoxynucleotidyl transferase (TdT), the
enzyme that carries out N-addition, is typically expressed at high-
est levels during H chain rearrangement in pro-B and large cycling
pre-B cells (28). Therefore, the presence of N-additions provides
indirect evidence that VHR occurred at the time when TdT was
active and therefore probably took place in pro-B or early pre-B
cells. Further evidence in support of VHR in early stage B cells
includes ligation-mediated PCR to measure DNA breaks at the
heavy chain locus, which occurred at the highest levels in pro-
B cells (29). These studies suggest that VHR is either occurring
in cells where IgH rearrangement has not yet shut down (failed
allelic exclusion) or is driven by pre-BCR rather than BCR signal-
ing, since only the former receptor is expressed at the pre-B cell
stage of development.
With respect to pre-BCR signaling [reviewed in Ref. (30)], it is
noteworthy that surrogate light chain knock-out mice have autore-
active antibodies with long CDR3 sequences (31). One potential
explanation for this result is that, in the absence of surrogate light
chain, the pre-BCR does not assemble and turn off heavy chain
rearrangement. Without a heavy chain rearrangement stop signal,
there may be higher frequencies of VHR, leading to CDR3 elonga-
tion. However, an alternative possibility is that peripheral selection
of B cells with long CDR3 sequences is relaxed in the lymphopenic
setting that arises due to inefficient primary B cell production
in surrogate light chain knock-out mice. It is known that in the
absence of normal numbers of peripheral B cells, the level of the B
cell survival factor BLyS (also known as BAFF) increases, since B
cells are the primary consumers of BLyS. It is also known that the
stringency of B cell selection can be reduced when BLyS levels are
increased (32, 33).
VH REPLACEMENT IN PERIPHERAL B CELLS
Some studies suggest that VHR could occur in more mature B
cell subsets. For example, there are data implicating BCR signaling
in VHR in the EU12 human B cell line, which phenotypically
resembles IgM+, CD10+, CD24high cells. In these cells, BCR
crosslinking promotes VHR and, conversely, Syk and Src kinase
inhibitors inhibit VHR (34). While some of the kinase inhibition
experiments could also be influencing mechanisms that operate at
earlier stages of B cell development, the BCR crosslinking exper-
iment suggests that BCR signaling could promote VHR in more
mature B cells. Furthermore, ligation-mediated PCR experiments
documented double-stranded DNA breaks at VH3 cRSS sites in
human immature (IgM+, CD27−, CD10+) and mature naïve
(IgM+, CD27−, CD10−) circulating B cells, also suggesting that
VHR may not be limited to immature B cells (34).
Chronic graft versus host disease (GVHD) is one of the most
intriguing examples in which VHR could be occurring in more
mature B cells (35). B6 mice injected with I–A incompatible T cells
from bm12 mice develop chronic GVHD and produce a spectrum
of autoantibodies that resembles those found in systemic autoim-
mune conditions such as systemic lupus erythematosus (SLE) (36).
When anti-dsDNA heavy chain knock-in mice such as 3H9 and
56R are used, GVHD occurs and the production of anti-nuclear
antibodies is enhanced (35). But the remarkable finding is that
among IgG antibodies, a large fraction does not use the knocked
in heavy chain (35). Although this unexpected skewing away from
the 56R H chain could be the result of selective pressures on
the minority population of H chain edited B cells that emerge
from the bone marrow, it is not at all obvious how this selec-
tion could operate to disfavor the transgene, and why its effects
would be largely confined to IgG and not IgM. It is possible that
the transgene was revised (by further gene rearrangement) in the
periphery, either because it was inactivated by somatic mutation
(37), or because the stimulus afforded by cGVH re-induced the
rearrangement machinery. An alternative explanation is that the
56R transgene bearing cells are disfavored during primary B cell
maturation because they recognize DNA and this self-reactivity
causes them to be anergized (this would predict that 56R+ cells
would be over-represented amongst IgM rather than IgG B cells).
Consistent with the possibility of anergy, most B cells express-
ing the IgM allotype of the 56R transgene have low levels of
IgM (38–40).
WHAT ARE THE CONSEQUENCES AND POTENTIAL
FUNCTIONS OF VH REPLACEMENT?
VH replacement allows a B cell with an inadequate pre-BCR or
an autoreactive BCR to swap out the existing heavy chain and
replace it with a different heavy chain. But why would this be
useful? One possibility is that VHR increases the odds of gener-
ating a functional antibody. Producing a functional antibody is
rather difficult (41): many rearrangements are out of frame, VH
pseudogenes outnumber functional VH genes, many newly gener-
ated antibodies are autoreactive (42), some combinations may be
sequestered inside the cells (38) and some H and L chain combi-
nations may not pair well with each other. VHR may also facilitate
the use of a wider array of upstream VH genes. By giving cells
with defective antibody rearrangements a chance at revising those
antibodies, perhaps the efficiency of primary B cell generation is
greatly improved.
On the other hand, a seemingly diametrically opposed con-
sequence of VHR is the potential generation of multireactive
antibodies. VHR can sometimes result in the retention of a “foot-
print” that is comprised of DNA sequences downstream of the
cryptic heptamer of the invaded VH gene (Figure 1). Because
the cRSS is typically positioned further from the WGXG motif
in the JH segment than the 5′RSS of a DH segment, VHR is
likely to produce longer CDR3 segments than primary rearrange-
ments. Not surprisingly, longer CDR3 sequences have a higher
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FIGURE 2 | (A) Longer CDR3 sequences have more footprints. Plotted are
the average numbers of footprint 5-mers per sequence. Sequences are
averaged at each CDR3 size by the number of sequences that have CDR3s of
that particular length. Blue dots are in-frame (IF) rearrangements and red dots
are out of frame (OF) rearrangements. We find a positive linear correlation
between the length of the CDR3 and the number of footprints (r 2 =0.89 for
IF, r 2 =0.7 for OF). The line describing this relationship has a slope of
0.06±0.008 for OF (red line) and 0.05± 0.008 for IF rearrangements (blue
line). (B,C) are two examples of the entire distribution of footprint numbers at
two positions – position 56 (red circle OF) and position 69 (blue circle IF).
Black stems indicate the numbers of footprints and red lines represent the fit
of a Poisson distribution (λ=1.57 and 2.74, respectively).
proportion of footprints (Figure 2), but this does not guarantee
that all long CDR3 are the product of VHR. Seventy-eight per-
cent of the potential footprint regions in functional human
VH genes contain an arginine codon, so footprint-containing
sequences often also harbor a larger number of charged residues.
Longer CDR3s have been associated with greater multireactiv-
ity, and such multireactive B cells are normally counter-selected
as B cells mature during normal B cell development (42). RA
patients have antibodies with unusual CDR3 sequences in their
synovium (17) and we have seen CDR3 sequences in patients
with SLE that have regions of sequence homology that could
arise due to VHR. For example, Figure 1C shows a rearrange-
ment from an expanded B cell clone in a patient with SLE that
appears to contain two footprint sequences (highlighted in yel-
low). Autoimmune-prone strains of mice have elongated CDR3s,
although many of these may arise through mechanisms other
than VHR, such as D–D fusion (43, 44). All of these findings
beg the question of whether such “multireactivity” serves a useful
function. Is multireactivity protective, particularly in the context
of an innate immune response? Or could multireactive anti-
bodies be useful in clearing debris that might be inflammatory
if left to accumulate? It is intriguing in this regard that some
multireactive IgM antibodies such as the famous T15 idiotype,
which binds phosphorylcholine (45), also have anti-inflammatory
properties (46).
It is possible that there is no simple single answer to the func-
tion of VHR, if it has one at all. It would certainly seem that
the biological consequences of VHR depend upon the develop-
mental context in which the rearrangement occurs. If replace-
ment occurs centrally, as is likely to occur in wild type strains
of mice such as B6 (40, 47), it could serve as a tolerance
mechanism (receptor editing) or as means of increasing the
efficiency of primary B cell generation. It might also gener-
ate a portion of the primary antibody repertoire that has spe-
cial functional properties such as multireactivity. Conversely, if
it occurs peripherally, as might arise in dysregulated states of
immune activation such as GVHD (48), perhaps autoimmunity
results.
VH REPLACEMENT IN pre-B CELL ALL
Given the abundance of findings linking VHR to pro- or pre-B cell
development discussed above, it is not surprising that the initial
demonstrations of VHR occurred in transformed pre-B cell lines.
More recently, VHR has been demonstrated to be a major contrib-
utor to clonal evolution in precursor B cell acute lymphoblastic
leukemia (B-ALL) (49, 50). In B-ALL, there is presumably a large
clone of cells “frozen” in the pre-B cell stage. The recombinase
machinery remains active in at least some of these cells and can
drive VHR. It is instructive to review the early work in the murine
pre-B cell line NFS5, in which VHR was found to alter not only
the productive but also the non-productively rearranged allele
(12). Thus assays where one attempts to define a clone based
upon its predicted “conservation” of other immunoglobulin gene
rearrangements (such as the other H chain allele) within the same
cell are not necessarily reliable or easy to interpret. The poten-
tial for VHR to contribute to intraclonal diversification is highly
relevant to the design and interpretation of assays for minimal
residual disease monitoring that employ quantitative PCR with
probes or primers for clone-specific junctional sequences (51) or,
more recently, high throughput sequencing of heavy chain CDR3
(52). Such studies must take VHR and other forms of intraclonal
diversification into account.
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Table 1 | Footprint sequences in the 3′ end of human germlineVH genes and alleles.
Footprint (5-mer variants) VH gene allele(s)
CGAGAGA (CGAGA, GAGAG, AGAGA) CGAGAGA VH1-18, VH1-2*1, VH1-2*2, VH1-2*3, VH1-2*5, VH1-3, VH1-46*1, VH1-46*2, VH1-69*1,
VH1-69*4, VH1-69*6, VH1-69*8, VH1-69*9, VH1-69*10, VH1-69*11, VH1-69*12, VH1-69*13,
VH1/OR15-1*2, VH1/OR15-1*3, VH1/OR15-1*4, VH3-11*1, VH3-11*4, VH3-11*5, VH3-21,
VH3-30*1, VH3-30*3, VH3-30*4, VH3-30*5, VH3-30*6, VH3-30*7, VH3-30*9, VH3-30*10,
VH3-30*11, VH3-30*12, VH3-30*13, VH3-30*14, VH3-30*15, VH3-30*16, VH3-30*17,
VH3-30*18, VH3-30*19, VH3-33*1, VH3-33*2, VH3-33*4, VH3-33*5, VH3-48, VH3-53*1,
VH3-53*4, VH3-64*1, VH3-64*2, VH3-64*4, VH3-66*1, VH3-66*3, VH3-7*1, VH3-7*3,
VH4-28*3, VH4-30-2*4, VH4-31*1, VH4-31*2, VH4-31*3, VH4-31*10, VH4-34*9, VH4-39*2,
VH4-39*6, VH4-39*7, VH4-4*2, VH4-4*6, VH4-4*7, VH4-59*1, VH4-59*2, VH4-61*1,
VH4-61*2, VH4-61*3, VH4-61*8, VH4/OR15-8, VH7-4-1*2, VH7-4-1*4, VH7-4-1*5
CGAGA VH1-2*4, VH1-69*2, VH1-69*5, VH1/OR15-1*1, VH3-11*3, VH3-30*8, VH3-30-3*1,
VH3-53*2, VH3-66*2, VH3-7*2, VH4-28*4, VH4-34*12, VH4-59*7, VH4-61*5, VH4-b,
VH5-51*3, VH5-51*4, VH5-a, VH7-4-1*1
CGAGAGG (CGAGA, AGAGG) VH1-8, VH4-34*1, VH4-34*2, VH4-34*4, VH4-34*5, VH4-34*13, VH4-59*9
CGAGACA (CGAGA, GAGAC, AGACA) VH3-66*4, VH4-30-2*3, VH4-39*1, VH4-59*8, VH4-61*7, VH5-51*1, VH5-51*2
CGAGATA (CGAGA, GAGAT, AGATA) VH4-34*10, VH4-59*10, VH7-81
CGAGAAA (CGAGA, GAGAA, AGAAA) VH4-28*1, VH4-28*2, VH4-28*5, VH4-28*6
CAAGANA (CAAGA, AAGAN, AGANA) CAAGANA VH1-45*1
CAAGATA VH1-45*2
CAAGAGA VH3-13*1, VH3-13*2, VH3-13*4, VH3-74*1, VH3-74*3, VH3/OR16-10*3, VH6-1
CAAGA VH1-45*3, VH3-13*3, VH3-74*2, VH3/OR16-10*1, VH3/OR16-10*2, VH3/OR16-12
CAACAGA CAACAGA VH1-24
CAACA VH1-f*1
CTAGAGA (CTAGA, TAGAG, AGAGA) CTAGAGA VH1-46*3, VH3-72*1, VH3/OR15-7*5
CTAGA VH3/OR15-7*1, VH3/OR15-7*2, VH3/OR15-7*3
CTAGGGA (CTAGG, TAGGG, AGGGA) VH3-53*3
CGAAAGA (CGAAA, GAAAG, AAAGA) CGAAAGA VH3-23*1, VH3-23*2, VH3-23*4, VH3-30*2, VH3-30-3*2, VH3-33*3, VH3-33*6, VH3-NL1
CGAAA VH3-23*3, VH3-23*5
CGNNN VH4-30-2*2, VH4-31*4, VH4-34*8, VH4-39*5, VH4-59*3, VH4-59*4, VH4-59*5, VH4-59*6,
CG VH4-31*5
CCAGATATA (CCAGA, CAGAT, AGATA,
GATAT, ATATA)
VH3-38
CCAGAGA (CCAGA, CAGAG, AGAGA) VH4-30-2*1, VH4-30-2*5, VH4-30-4*1, VH4-30-4*2, VH4-30-4*5, VH4-30-4*6, VH4-61*6
TGAAACA (TGAAA, GAAAC, AAACA) TGAAA VH3/OR16-8*1, VH3/OR16-9
TGAAACA VH3/OR16-8*2
TGAGA
TGAGAGA (TGAGA, GAGAG, AGAGA) TGAGA VH1/OR15-5
TGAGAGA VH1/OR15-9, VH1/OR21-1
TGAGAAA (TGAGA, GAGAA, AGAAA) VH3-16, VH3-35
TGAAAGA (TGAAA, GAAAG, AAAGA) VH3-64*3, VH3-64*5
CGGCAGA (CGGCA, GGCAG, GCAGA) VH1-58
CACGGATAC (CACGG, ACGGA, CGGAT,
GGATA, GATAC)
VH2-26, VH2-70*1, VH2-70*10, VH2-70*11
(Continued)
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Table 1 | Continued
Footprint (5-mer variants) VH gene allele(s)
CATGGAGAG (CATGG, ATGGA, TGGAG,
GGAGA, GAGAG)
VH2/OR16-5
TACGG VH2-5*4, VH2-70*9
TANNN VH2-5*7
CACGG VH2-5*10
CACACAGACC (CACAC, ACACA,
CACAG, ACAGA, CAGAC, AGACC)
CACACAGACC VH2-5*1
CACACAGAC VH2-5*5, VH2-5*8, VH2-5*9, VH2-70*12
CACACAGA VH2-5*6
CAAAAGATA (CAAAA, AAAAG, AAAGA,
AAGAT, AGATA)
VH3-43, VH3-9
Two hundred and seventy-three functional VH genes, including alleles and sequences designated as open reading frames, were downloaded from the IMGT database
(54) and manually scanned for footprints. A footprint is defined by the nucleotide sequence following the cryptic recombination signal sequence (cRSS), TACTGTG,
at the 3′ end of each VH, and is listed in the left column of the table. The footprint 5-mer variants that were used to scan the sequences are included in parentheses.
The right column lists the VH genes and alleles. An asterisk in the VH name refers to a specific allele. If all alleles of a particular VH have the same footprint, allele
names are omitted. Overlapping footprints are listed for some footprints in the sub-column on the right. Footprints in red font are also found in germline DH and
JH gene segments. Sequences with ambiguous nucleotide designations (N-nucleotides) are indicated by italic font. The following VH gene alleles do not have a
cRSS: VH1-18*2, VH1-69*3, VH1-69*7, VH1-c, VH1-f*2, VH2-5*2, VH2-5*3, VH2-70*2, VH2-70*3, VH2-70*4, VH2-70*5, VH2-70*6, VH2-70*7, VH2-70*8, VH2-70*13,
VH3-15, VH3-20, VH3-25*4, VH3-49, VH3-72*2, VH3-73*1, VH3-73*2, VH3-d, VH3/OR16-13, VH3/OR16-6*2, VH4-30-4*3, VH4-30-4*4, VH4-31*6, VH4-31*7, VH4-31*8,
VH4-31*9, VH4-34*3, VH4-34*6, VH4-34*7, VH4-34*11, VH4-39*3, VH4-39*4, VH4-4*1, VH4-4*3, VH4-4*4, VH4-4*5, VH4-61*4, VH5-51*5, VH7-4-1*3.
ANALYSIS OF VH REPLACEMENT FOOTPRINTS
The most convincing demonstrations of VHR are those in which a
precursor–product relationship can be documented. For example,
if the precursor VH gene is known and then additional B cells
can be found to share most of the 3′ side of the CDR3 (the
same DH–JH junction), but have a different VH gene, this can
be compelling, as in B-ALL or in mouse models with heavy
chain knock-ins. In contrast, the analysis of VHR in a physi-
ologic and fully diversified immune repertoire has by necessity
focused on indirect evidence, namely the enumeration of foot-
prints, which are potential traces of previous VDJ rearrangements
in IgH sequence data. In mice, footprints are readily observed
in constrained immune repertoires [for example, Ref. (13, 15,
23)]. Footprints are also observed in humans (53). However, a
fundamental issue with footprint analysis in humans is one of
specificity of attribution: does the footprint arise due to VHR
or is it due to some other form of junctional diversification
or skewing in the rearrangement process? Or does it occur by
chance?
To investigate the hypothesis that footprint sequences are due
to the process of VHR, we sequenced IgH rearrangements from
peripheral blood B cells of a healthy human adult subject, fol-
lowing an IRB-approved protocol. We identified 42,221 unique
sequences from this sample, which we analyzed for VH footprints
using a sliding window method (see Supplementary Material
for further details). All of the potential footprints arising from
sequences at the 3′ ends of the germline VH genes are listed
in Table 1. In accordance with their conventional description
in the literature (41), we required the footprint to be least five
nucleotides long (we hereafter refer to these sequences as foot-
print 5-mers). If footprint 5-mers are due to VHR, they will have
specific characteristics in antibody repertoire data, indicated by
the tests described below.
TEST 1: VH REPLACEMENT FOOTPRINTS SHOULD BE LOCATED IN THE 5′
END OF THE CDR3 SEQUENCE
One way to distinguish bona fide footprints from other sources of
sequence variation is to compare the number of footprints in the
junction between VH and DH (referred to as N1) to the number
in the junction between DH and JH (referred to as N2). Footprints
arising via VHR should occur in N1 rather than N2 because the
cryptic heptamer is located in N1. However, as shown in Figure 3A,
there is a roughly bimodal distribution of footprint 5-mers. Even
though we excluded the most common footprints that were found
in the germline DH gene segments (Table 2), there were still plenty
of footprint sequences in N1, DH, and N2. In Figure 3B we took
the analysis one step further and removed some more of the com-
mon footprint sequences that are found not only in the germline
DH gene segments but also in JH6. This resulted in more skewing
toward N1, but a large proportion of the footprints were still out-
side of N1. In fact, not only were footprint 5-mers found in DH
and JH, but they were also found in other parts of the VH gene.
Table 3 lists the positions of all of the footprint 5-mers found
amongst the germline VH alleles listed in the IMGT database.
TEST 2: VH REPLACEMENT FOOTPRINTS SHOULD BE MORE FREQUENT
IN UPSTREAM VH GENES THAN DOWNSTREAM VH GENES AND
ABSENT FROM VH6-1
Another requirement for a footprint to be consistent with VHR is
that the invading VH must be upstream of the VH that donated
the footprint. Unfortunately, the recipient VH is often difficult to
define because many VHs have the same or very similar footprints
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FIGURE 3 | Positions of footprint 5-mers. (A) Frequency distribution of all
footprint 5-mers out of total unique sequences (n=42,221) plotted against
the normalized CDR3 position. The CDR3 is herein defined to begin at the
conserved CAR amino acid sequence (TGT GCG AGA nucleotide sequence)
within the 3′ end of VH and end at the conserved W (TGG nucleotide
sequence) that is immediately upstream of the first conserved glycine, GGC
nucleotide sequence) within the JH. “TGGAG” is excluded as it is found in
many alleles of all DH genes. The position of the footprint is defined by where
the footprint starts within the CDR3. For example, if a footprint occupies
nucleotides 12–16 of the CDR3, it will be plotted at position 12. CDR3 lengths
were normalized to a scale of 1–100 using p1=p/(L×100); where p is the
position of the 5-mer in the real CDR3 sequence, L is the length of the CDR3
sequence, and p1 is the normalized position. Normalized positions are
rounded to the nearest integer. (B) Frequency distribution of all footprint
5-mers plotted against the normalized CDR3 position, corrected for footprint
5-mers in the germline JH6 gene. “ATGGA,” “TACGG,” and “CATGG” were
excluded when found in the 3′ end of the CDR3 within the JH6 gene, as
these 5-mers are found in the germline JH6 sequence. Footprint 5-mers
found in other JHs (seeTable 2) are not counted in either (A) or (B) because
they are all located outside CDR3 region of JH.
(see Table 1). However, a more straightforward test of whether
a footprint 5-mer represents the product of VHR is to evalu-
ate the frequency of footprints in different VH rearrangements.
In particular, the 3′ most VH gene (VH6-1, in humans), when
rearranged, should not exhibit VHR footprints as there is no
downstream VH that it can invade. Conversely, VH genes that
are situated in the 5′ end of the locus should have higher fre-
quencies of footprints than 3′ VH genes, if VHR is frequent. Yet
the overall frequency of footprint 5-mers was similar amongst
unique sequences in all of the most commonly used VHs, includ-
ing VH6-1 (Figure 4). The frequency of footprints was also not
significantly higher in out of frame (unselected) versus in-frame
rearrangements (Figure 4A).
We also performed this analysis using immunoglobulin analy-
sis tool (IgAT) software (42) and observed that the frequency of
footprints was not reduced in VH6-1 when compared to other
VHs (Figure 4B). Lower VH footprint frequencies were observed
overall because footprints in the 3′ end of the CDR3 are excluded
by the IgAT program (42). One intriguing feature of the IgAT data
was that, unlike our footprint analysis that captured 5-mers at
both N1 and N2, when only N1 was analyzed, some VHs, includ-
ing VH6-1, had higher footprint frequencies than others. Since
VH6-1 cannot have any footprints due to VHR, we conclude that
many footprint 5-mers that are found in the CDR3 do not arise
by VHR.
The simplest explanation is that the great majority of 5-mer
sequences found throughout the CDR3 resemble footprints by
chance. The frequency of footprint 5-mers in the entire CDR3
was highly correlated with the length of the CDR3 (Figure 2).
The ability to generate a replacement footprint by chance may be
www.frontiersin.org January 2014 | Volume 5 | Article 10 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meng et al. Trials and tribulations with VH replacement
Table 2 | Footprint sequences in DH and JH alleles.
DH gene Sequence (footprint(s) in red font)
D1-1*01 GGTACAACTGGAACGAC
D1-14*01 GGTATAACCGGAACCAC
D1-20*01 GGTATAACTGGAACGAC
D1-26*01 GGTATAGTGGGAGCTACTAC
D1-7*01 GGTATAACTGGAACTAC
D2-15*01 AGGATATTGTAGTGGTGGTAGCTGCTACTCC
D2-2*01 AGGATATTGTAGTAGTACCAGCTGCTATGCC
D2-2*02 AGGATATTGTAGTAGTACCAGCTGCTATACC
D2-2*03 TGGATATTGTAGTAGTACCAGCTGCTATGCC
D2-21*01 AGCATATTGTGGTGGTGATTGCTATTCC
D2-21*02 AGCATATTGTGGTGGTGACTGCTATTCC
D2-8*01 AGGATATTGTACTAATGGTGTATGCTATACC
D2-8*02 AGGATATTGTACTGGTGGTGTATGCTATACC
D3-10*01 GTATTACTATGGTTCGGGGAGTTATTATAAC
D3-10*02 GTATTACTATGTTCGGGGAGTTATTATAAC
D3-16*01 GTATTATGATTACGTTTGGGGGAGTTATGCTTATACC
D3-16*02 GTATTATGATTACGTTTGGGGGAGTTATCGTTATACC
D3-22*01 GTATTACTATGATAGTAGTGGTTATTACTAC
D3-3*01 GTATTACGATTTTTGGAGTGGTTATTATACC
D3-3*02 GTATTAGCATTTTTGGAGTGGTTATTATACC
D3-9*01 GTATTACGATATTTTGACTGGTTATTATAAC
D4-11*01 TGACTACAGTAACTAC
D4-17*01 TGACTACGGTGACTAC
D4-23*01 TGACTACGGTGGTAACTCC
D4-4*01 TGACTACAGTAACTAC
D5-12*01 GTGGATATAGTGGCTACGATTAC
D5-18*01 GTGGATACAGCTATGGTTAC
D5-24*01 GTAGAGATGGCTACAATTAC
D5-5*01 GTGGATACAGCTATGGTTAC
D6-13*01 GGGTATAGCAGCAGCTGGTAC
D6-19*01 GGGTATAGCAGTGGCTGGTAC
D6-25*01 GGGTATAGCAGCGGCTAC
D6-6*01 GAGTATAGCAGCTCGTCC
D7-27*01 CTAACTGGGGA
JH gene Sequence (footprint(s) in red font)
J1*01 GCTGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTC
ACCGTCTCCTCAG
J2*01 CTACTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTC
ACTGTCTCCTCAG
J3*01 TGATGCTTTTGATGTCTGGGGCCAAGGGACAATGGTCACCG
TCTCTTCAG
J3*02 TGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCG
TCTCTTCAG
J4*01 ACTACTTTGACTACTGGGGCCAAGGAACCCTGGTCACCGTCT
CCTCAG
J4*02 ACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCT
CCTCAG
J4*03 GCTACTTTGACTACTGGGGCCAAGGGACCCTGGTCACCGTCT
CCTCAG
(Continued)
JH gene Sequence (footprint(s) in red font)
J5*01 ACAACTGGTTCGACTCCTGGGGCCAAGGAACCCTGGTCACC
GTCTCCTCAG
J5*02 ACAACTGGTTCGACCCCTGGGGCCAGGGA
ACCCTGGTCACCGTCTCCTCAG
J6*01 ATTACTACTACTACTACGGTATGGACGTCTGGGGGCAAGGGA
CCACGGTCACCGTCTCCTCAG
J6*02 ATTACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGA
CCACGGTCACCGTCTCCTCAN
J6*03 ATTACTACTACTACTACTACATGGACGTCTGGGGCAAAGGGA
CCACGGTCACCGTCTCCTCAN
J6*04 ATTACTACTACTACTACGGTATGGACGTCTGGGGCAAAGGGA
CCACGGTCACCGTCTCCTCAG
Thirty-four germline functional human DH alleles and 13 JH alleles were down-
loaded from the IMGT database (54). Each allele was scanned for all of the
possible five nucleotide footprint motifs listed inTable 1. Sequences containing
five nucleotide footprints are given in red font. In some cases the region matches
more than one possible footprint (for example, D5-12*01 contains three different
footprints: GGATA, GATAT, and ATATA).
under-appreciated. In a completely random DNA sequence with
equal proportions of A, T, G, and C bases, the chance of finding a
specific 5-mer sequence is 1/1,024 (or ~0.001). However, there are
at least 50 different footprint-derived 5-mer sequences amongst
human VH genes (Table 3), increasing the odds to 50/1,024
(~5%). But this calculation ignores the number of different posi-
tions along the VDJ rearrangement where the footprint might be
detected and on how many variants of the footprint are permit-
ted. If the 5′ end of a CDR3 sequence is 30 nucleotides long, that
means that there are 6 completely non-overlapping sequences that
have a length of five nucleotides, bringing the minimum likelihood
of detection of at least a single footprint in that sequence up to
26% [1−(1−0.05)6] or 1−Pr(not getting any 5-mers in the 30 bp
sequence). If the base composition of the DNA is non-uniform or
the entire CDR3 sequence is surveyed or if sequences with muta-
tions are permitted (for example those matching in 4 out of 5 bp),
the chances of detecting a footprint increase even further.
We also wondered why some VH genes had higher footprint
frequencies in N1 than others (Figure 4B), as this finding is not
similar to what one would expect by random chance. We won-
dered if the real VHR events were hiding somewhere in a large pile
of non-VHR footprints. A high “false positive” rate of footprint
5-mers could come about because of sequencing errors. Alterna-
tively or in addition, it may be easy to create false VHR 5-mer
sequences in primary VDJ rearrangements through a combina-
tion of N-addition, nibbling (or sequencing deletion) and the 3′
sequence of the VH. For example AAAGA could become AAGA
or AGA.
It may be worthwhile to develop a better computational
approach for detecting VHR footprints with greater specificity for
VHR. The IgAT software already eliminated footprints that match
the germline VH sequence exactly, but this is insufficient, give the
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Table 3 |The number of footprints found in various regions of humanVH genes.
Footprint Sequences FR CDR FR1 FR2 FR3 CDR1 CDR2 CDR3
TGAGA 131 212 12 94 118 3 3 6
CTAGAGA 8 8 8
CGAAAGA 9 9 9
CTAGA 28 17 16 17 1 1 14
TACGG 9 5 4 1 4 1 1 2
CAAAA 45 41 13 41 9 4
CTAGGGA 2 1 1 1 1
CAACA 55 33 27 1 5 27 2 23 2
CAAGA 150 149 18 4 145 3 15
CACACAGA 20 20 6 20 6
CGAGACA 7 7 7
CGAGAAA 3 3 3
TGAAAGA 2 2 2
TGAAACA 3 3 2 1
CGAGAGG 8 2 6 2 6
CGAGAGA 86 86 86
CACGG 179 178 6 178 6
CGAGATA 3 3 3
CGAAA 11 11 1 10
TGAAA 61 79 7 33 46 1 3 3
CACACAGAC 20 20 5 20 5
CGAGA 130 3 127 1 2 127
CACACAGACC 20 20 1 20 1
TGAGAAA 6 6 3 3
CAAAAGATA 3 3 3
CGGCAGA 2 2 2
TGAGAGA 3 1 2 1 2
CCAGATATA 2 2 2
CAAGATA 1 1 1
CCAGAGA 84 80 4 80 4
CACGGATAC 5 5 5
CAAGAGA 27 19 8 19 8
Two hundred and thirty-four functional germline human VH alleles were downloaded from the IMGT database (54). For each footprint, the number of times that
footprint was found in the VH alleles was recorded. The first column lists the footprint, the second column lists the number of alleles in which the footprint is found.
Some alleles contain more than one footprint. The remaining columns indicate how many footprints were found in each of the corresponding regions of the V region.
FR, framework; CDR, complementarity determining region. The columns named FR and CDR provide the total number of times that a particular footprint is found in
the FR or the CDR.
high frequency of footprints in N1 of VH6-1. Further specificity
might be achievable if one were to limit the detection of footprint
5-mers to sequences that are unlikely to arise through a single
nucleotide change (for example, those that arise by deletion that
converts a non-matching 6-mer to a matching 5-mer, or muta-
tion of a non-matching 5-mer to a footprint 5-mer or N-addition
of a nucleotide adjoining a 4-mer to create a footprint 5-mer).
An alternative approach is to require that there be two footprint-
like sequences in tandem. Either or both of these methods might
increase specificity, but could also reduce sensitivity of footprint
detection. The validity of either approach would need to be tested
further using validated data sets in which VHR events are known
to have or have not occurred.
We also considered the possibility that footprint 5-mers may
frequently arise through some mechanism other than VHR.
We considered two potential alternative mechanisms – (1)
microhomology-mediated joining and (2) cleavage, nibbling, and
rejoining at the cryptic heptamer.
ALTERNATIVE THEORY 1: MICROHOMOLOGY-MEDIATED JOINING
We considered the possibility that footprints at N1 were aris-
ing primarily due to microhomology-mediated joining of sim-
ilar sequences between the VH and the DH segments. If
microhomology-mediated joining were common, one might
expect that VHs that share the same 5-mers with DHs are more
likely to rearrange, but as shown in Figure 5, this is probably
not usually the case. DH5-12 (open bars in Figure 5), which
has three footprint 5-mers, does not appear to be used more
frequently in rearrangements involving VHs that contain the
same 5-mers such as VH2-26 (red arrow). Rather than being
www.frontiersin.org January 2014 | Volume 5 | Article 10 | 9
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FIGURE 4 | (A) Percentage of rearrangements with footprints for the 10
most frequent VH rearrangements and VH6-1. The percentages of
rearrangements that contain at least one footprint 5-mer in either (or both)
the 5′ end or the 3′ end of the rearrangement are shown for unique
rearrangements for each of the 10 most common VH genes and for VH6-1.
CDR3 sequences are defined as described in the legend to Figure 3 and
normalized to an arbitrary length of 100. The 5′ end (which almost always
contains N1) is defined as the first 20% of the sequence and the 3′ end is
defined as the last 20% of the sequence (which almost always contains
N2). VH6-1 is the most 3′ VH gene and cannot contain footprints that are
due to VH replacement. Black bars denote unique rearrangements that are
in-frame (IF VH), white bars denote out of frame rearrangements (OF VH),
and gray bars indicate total unique rearrangements (total VH). (B) Footprint
Frequency of in-Frame VH rearrangements in N1 using IgAT Software. The
same unique in-frame (IF) VH rearrangements, as shown in (A), were
analyzed for the presence of one or more footprints using IgAT software (2).
Plotted are the frequencies of unique IF VH rearrangements that have one
or more footprints in the N1 region.
skewed toward particular VHs with matching or similar footprints,
the frequency of rearrangements of different VHs to DH5-12
rearrangements resembled overall VH usage (Figure 5, closed
bars). While this analysis is very preliminary and only focused
on a single DH, it suggests that microhomology-mediated join-
ing, based upon shared sequences between VH and DH, is not a
frequent mechanism for generating footprint 5-mers.
ALTERNATIVE THEORY 2: CLEAVAGE, NIBBLING, AND REJOINING AT
THE CRYPTIC HEPTAMER IN VH
We wondered if there could be cleavage at the cryptic heptamer,
followed by exonucleolytic nibbling and re-sealing at the site of
the break, without full-blown rearrangement (Figure S1 in Supple-
mentary Material illustrates this idea for a VH6-1 rearrangement).
Note that this type of rearrangement product would not involve
VHR, but would have the result of diversifying the 3′ end of the
VH in the primary rearrangement product, altering the primary
amino acid sequence and/or the reading frame of the rearrange-
ment. This hypothesis makes predictions regarding the sequence
characteristics that would be more or less amenable to this type of
atypical open-and-shut joint (2). For example, one would expect
that if most footprint 5-mers at N1 arise by this mechanism, that
the frequency of footprint 5-mers would be very low in VH genes
that lack cryptic heptamers. Furthermore, one would expect that
the 5′ footprint 5-mer seen in most rearrangements would resem-
ble the 3′ end of the germline sequence of the same VH gene that
is present in the rearrangement.
PRELIMINARY CONCLUSIONS AND CAVEATS FROM FOOTPRINT
ANALYSIS
Taken together, these data suggest that many if not most foot-
print sequences arise by some mechanism(s) other than VHR. But
there are some caveats to this analysis. First, these data were only
obtained on one healthy adult. It is possible that footprints may dif-
fer in other individuals or in a minority of individuals. In addition,
different findings might occur in individuals with immunologic
disorders such as SLE or neoplastic conditions such as B-ALL.
Furthermore, only B cells from the peripheral blood were ana-
lyzed. It is conceivable that B cell populations with extensive VHR
reside elsewhere in the body, particularly within the bone marrow.
Finally, as discussed above, it is possible that some of the VHR
footprints that were identified are due to sequencing errors. We
tried to protect against this artifact by selectively analyzing unique
sequences that were present in at least two copies. But even with
this precaution, there are still likely to be many sequencing errors.
CONCLUSION
VH replacement exchanges the VH within a pre-existing VDJ
rearrangement with an upstream VH gene, while preserving most
of the original CDR3 sequence. It also sometimes results in the
retention of a footprint sequence in the VH gene that was invaded.
The result of VHR is an alteration in the specificity or functional
status of the antibody. But the mechanistic consequence of that
alteration is unclear. Is it to diversify the repertoire once a good
CDR3 sequence has been found? Or is it to reduce autoreactivity
or generate some form of protective multireactivity? Or is it sim-
ply a means by which B cells with non-productive rearrangements
on one or both alleles have another shot at creating a productive
rearrangement? In humans, the analysis of VHR is confounded
by not having a means of definitively identifying the precursor
rearrangement. Rather, the analysis of VHR in humans is accom-
plished indirectly through footprint analysis, but as demonstrated
herein, footprints may arise for reasons other than VHR. Thus,
while VHR certainly occurs, footprint analysis is a poor measure
of its frequency because of the high rate of false positives and
an unknown rate of false negatives. Nevertheless, it is possible
that footprints may provide other insights into the mechanisms
of V(D)J recombination and its potentially aberrant regulation in
disease states. With the advent of high throughput sequencing
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FIGURE 5 |VH usage is similar in all unique rearrangements and in rear-
rangements with DH5-12. VH usage is shown for total unique sequences
(closed bars, n=42,221) and for those with DH5-12 (open bars, n=1,029).
Sequences containing the DH5-12 gene segment in the CDR3 region were
recognized using IMGT high V quest analysis, and further analysis on VH
usage was performed in-house (see text). The red arrow points to VH2-26,
which contains some of the same footprint 5-mers as DH5-12, but does not
appear to be used more frequently in rearrangements that include DH5-12.
studies, further analysis of IgH gene rearrangements for VHR
and other mechanisms of CDR3 diversification promise to be
illuminating.
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Figure S1 | Model for atypical open-and-shut joints. Footprint 5-mers can be
generated by cleaving at the cryptic heptamer, followed by preferential trimming
by exonucleolytic nibbling at the 3′ end of the double strand break. Shown is the
generation of a footprint sequence in a VH6-1 rearrangement. The cryptic
heptamer is indicated by a dashed triangle, colored squares indicate the VH,
DH, and JH gene segments (not drawn to scale). According to this model, there
is cleavage at the cryptic heptamer, followed by nibbling at the 3′ end of the
break (red wavy line), leading to selective loss of the A residue. The third line of
the figure shows the repaired rearrangement, in which the A residue is missing
from the rearrangement.
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